Updates are available Correction dated 2022-12-28

Article History

Received: 9 December 2021

Accepted: 28 April 2022

First Online: 23 May 2022

Change Date: 28 December 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41746-022-00744-0

Competing Interests

: All authors with Verily affiliation are current Verily employees and are Verily shareholders. The study is financially supported by Verily Life Sciences LLC, Radboud University Medical Center, Radboud University, the city of Nijmegen, and the Province of Gelderland. Radboud UMC received funding for the original cohort from Health Holland (PPP allowance; public-private partnership), Radboud University Radboudumc, and Radboudumc (in kind). The other study sponsors had no role in study design and collection, analysis and interpretation of data, or in writing the manuscript. Prof. Bloem serves as the co-Editor in Chief for the Journal of Parkinson’s disease, serves on the editorial board of Practical Neurology and Digital Biomarkers, has received fees from serving on the scientific advisory board for UCB, Kyowa Kirin, Zambon, and the Critical Path Institute (paid to the. Institute), has received fees for speaking at conferences from AbbVie, Biogen, UCB, Zambon, Roche, GE Healthcare, Oruen and Bial (paid to the Institute), and has received research support from the Netherlands Organization for Health Research and Development, the Michael J Fox Foundation, UCB, the Stichting Parkinson Fonds, Hersenstichting Nederland, de Stichting Woelse Waard, Stichting Alkemade-Keuls, de Maag Lever Darm Stichting, Parkinson NL, Davis Phinney Foundation, the Parkinson’s Foundation, Verily Life Sciences, Horizon 2020, the Topsector Life Sciences and Health, Nothing Impossible and the Parkinson Vereniging, outside the submitted work. Prof. Bloem does not hold any stocks or stock options with any companies that are connected to Parkinson’s disease or to any of the topics in this paper. Prof. Bloem has received grants/research support from Netherlands Organization for Scientific Research, the Michael J Fox Foundation, Nothing Impossible, Parkinson Vereniging, Parkinson’s Foundation, Hersenstichting Nederland, Davis Phinney Foundation, Parkinson NL, Stichting Woelse Waard, Stichting Alkemade-Keuls, Maag Lever Darm Stichting, Verily Life Sciences, Horizon 2020, Topsector Life Sciences and Health, UCB, Zambon. Prof. Bloem has been a consultant for the Critical Path Institute, Kyowa Kirin, UCB, Zambon, and has received speaking fees from AbbVie, Bial, Biogen, GE Healthcare, Oruen, Roche, UCB, Zambon. The remaining authors declare no competing interests.

: The study is being conducted in conformance with the Good Clinical Practice ICH E6 guideline and in compliance with the Ethical Principles for Medical Research Involving Human Subjects, as defined in the Declaration of Helsinki (version amended in October 2013), the Dutch Personal Data Protection Act, and the European General Data Protection Regulation. The Commissie Mensgebonden Onderzoek Region Arnhem-Nijmegen approved the study protocol and communication materials²⁷. Signed informed consent is obtained before engaging a participant in any study procedure, including use of the PD-VME.